Other Information
−Removed: During the quarter ended March 31, 2024, none of the Company’s directors or officers has adopted or terminated a Rule 10b5-1
−Removed: trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Exchange Act).
+Added: Other than as set forth below, during the quarter ended June 30, 2024, none of the Company’s directors or officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each
+Added: as defined in Item 408 of Regulation S-K under the Exchange Act).
+Added: In May 2024, the Company established a mandatory sell-to-cover policy to satisfy tax withholding obligations for employee RSU awards.
+Added: The trading arrangements pursuant to this policy constitute non-Rule 10b5-1 trading
+Added: arrangements.
+Added: Ocuphire Pharma, Inc.
DESCRIPTION OF DOCUMENT
−Removed: Third Amendment to the Consulting Agreement, dated as of January 1, 2024, by and between the Company and Jay Pepose, M.D.
−Removed: Employment Agreement, dated as of February 13, 2024, by and between the Company and Nirav Jhaveri (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on February 16, 2024).
−Removed: First Amendment to Employment Agreement, dated as of February 16, 2024, by and between the Company and Nirav Jhaveri (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on February 16, 2024).
−Removed: Consulting Agreement, dated as of April 11, 2024, by and between the Company and Jay Pepose, M.D.
−Removed: (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on April 17, 2024).
+Added: Restated Certificate of Incorporation of Ocuphire Pharma, Inc., dated as of June 12, 2024
+Added: Third Amended and Restated Bylaws, dated as of June 11, 2024 (incorporated by reference to Exhibit 3.2 of Registrant’s Current Report on Form 8-K, filed on June 13, 2024).
+Added: Third Amended and Restated Non-Employee Director Compensation Plan, dated as of June 11, 2024.
+Added: Consulting Agreement, dated as of April 11, 2024, by and between the Company and Jay S.
+Added: (incorporated by reference to Exhibit 10.1 of the
+Added: Registrant’s Current Report on Form 8-K filed on April 17, 2024).
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
8 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
−Removed: Indicates management contract or compensatory plan.
Documents are furnished not filed.
−Removed: Filed herewith.
+Added: Indicates exhibits that are being filed herewith.
+Added: Indicates management contract or compensatory plan.
Ocuphire Pharma, Inc.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 13, 2024
Ocuphire Pharma, Inc.
7 unchanged sentences
(Principal Financial Officer)
−Removed: /s/ Amy Rabourn
−Removed: Senior Vice President of Finance
−Removed: (Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.